Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together with previous reports, the present results suggest that two key transcription factors for the plasmacytic differentiation, XBP1 and BLIMP1, are involved in the pathogenesis in diffuse large B-cell lymphoma.
|
19380033 |
2009 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Unexpectedly, a subset of diffuse large B-cell lymphoma expressed PRDM1, lacked detectable plasmablastic or immunoblastic changes and displayed more aggressive behavior, with a shorter failure-free survival.
|
16585013 |
2006 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRDM1/Blimp-1 is a tumor suppressor gene in the activated B-cell subtype of diffuse large B-cell lymphomas.
|
25382611 |
2014 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A minority of diffuse large B-cell lymphomas expressed PRDM1 and Hodgkin lymphomas were largely PRDM1-.
|
15772984 |
2005 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, new roles for Blimp-1 have been revealed, as a suppressor of diffuse large B cell lymphoma and as a key regulator of T-cell differentiation.
|
17291741 |
2007 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for BLIMP-1 protein expression.
|
27568520 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRDM1/Blimp-1, a master regulator in terminal B-cell differentiation, has been recently identified as a tumor suppressor target for mutational inactivation in diffuse large B-cell lymphomas of the activated B-cell type.
|
18583325 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PRDM1 gene was found homozygously deleted in a case of DLBCL.
|
18297524 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BLIMP1 is frequently inactivated in a variety of lymphomas, including diffuse large B cell lymphomas, Natural Killer cell lymphoma and anaplastic large T cell lymphoma.
|
25115512 |
2015 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tumor suppressors B-lymphocyte-induced maturation protein-1 (BLIMP-1) and p53 play a crucial role in B-cell lymphomas, and their inactivation contributes to the pathogenesis of a wide spectrum of lymphoid malignancies, including diffuse large B-cell lymphomas (DLBCLs).
|
28474779 |
2017 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study identifies PRDM1 inactivation as a recurrent genetic defect in DLBCL cells and establishes PRDM1 as a potential tumor suppressor gene in DLBCL.
|
16424392 |
2006 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, abnormal epigenetic down-regulation of PRDM1 by let-7 and other microRNAs may represent an alternative mechanism of reducing normal PRDM1 function in a subset of DLBCL with relatively high PRDM1alpha mRNA expression and unmutated PRDM1.
|
20651244 |
2010 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PRDM1/Blimp1 is a master regulator of terminal B cell differentiation and may also function as a tumor suppressor in the pathogenesis of DLBCL, where it is frequently inactivated by mutations and deletions.
|
21722313 |
2011 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We report here that the BLIMP1 gene is inactivated by structural alterations in 24% (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell-like (n = 0/37) or unclassified (n = 0/21) DLBCL.
|
16492805 |
2006 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRDM1 protein expression was recently demonstrated in a subset of diffuse large B-cell lymphoma (DLBCL) with aggressive behavior, a type of lymphoma for which rituximab associated with chemotherapy (R-CHOP) is now widely indicated.
|
17379744 |
2007 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recently, mutational inactivation of Blimp-1 has been identified in a subset of diffuse large B-cell lymphomas of the activated B-cell type.
|
20047096 |
2010 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Discordance of PRDM1 messenger RNA and protein expressions is associated with high EBV-miR-BHRF1-2 levels in LCLs and primary post-transplant EBV-positive DLBCL.
|
26530011 |
2016 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe novel mutations in the BLIMP1 gene in 2 of 15 (13%) cases of B-cell lymphoma (two cases of primary effusion lymphoma and 13 cases of diffuse large B-cell lymphoma).
|
17213024 |
2007 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|